ADx NeuroSciences

ADx NeuroSciences, founded in 2008 and based in Ghent, Belgium, is a specialized diagnostics company developing innovative biomarker assays for neurodegenerative disorders like Alzheimer's, Parkinson's, and Motor Neuron Diseases. Its core capabilities include proprietary antibody generation and the development of robust, fit-for-purpose immunoassays tailored for drug development and clinical research. Operating as a Fujirebio company, ADx serves pharmaceutical clients and technology providers, aiming to improve clinical trial success and patient outcomes through precise biomarker measurement.

Proprietary antibody generation and fit-for-purpose immunoassay development platform for quantifying protein biomarkers in neurological diseases. Expertise includes epitope selection, antibody pairing, and assay optimization adaptable to various analytical platforms.

ADx competes in the neurodiagnostic and biomarker services market against large-cap diagnostic companies (e.g., Roche, Quanterix) and specialized assay developers. Its differentiation lies in its deep neuroscience-specific antibody expertise, fit-for-purpose service model for pharma, and the commercial backing of Fujirebio, which provides scale and regulatory experience.